Tag: Gilead Sciences

Gilead Sciences to acquire HDV drug developer MYR in €1.4bn deal

pharmanewsdaily- December 12, 2020 0

Gilead Sciences acquisition of MYR : US biopharma giant Gilead Sciences has agreed to acquire MYR, a German biotech company engaged in developing therapies for ... Read More

Gilead Sciences wraps up $21bn acquisition of Immunomedics

pharmanewsdaily- October 24, 2020 0

Gilead Sciences has wrapped up its previously announced $21 billion acquisition of New Jersey-based biopharma company Immunomedics. With the completion of the deal, Immunomedics has ... Read More

Gilead Sciences bags Remdesivir FDA approval for Covid-19 treatment

pharmanewsdaily- October 24, 2020 0

Remdesivir FDA approval : Gilead Sciences, a California-based biopharma company, has bagged approval from the US Food and Drug Administration (FDA) for its antiviral drug ... Read More

Gilead, Galapagos bag Jyseleca EC approval for rheumatoid arthritis

pharmanewsdaily- September 27, 2020 0

Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission ... Read More

Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy

pharmanewsdaily- September 14, 2020 0

Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to ... Read More

Pfizer to manufacture Gilead’s Covid-19 drug candidate remdesivir

pharmanewsdaily- August 8, 2020 0

Pfizer has signed a multi-year agreement with Gilead Sciences to manufacture and supply the latter's investigational antiviral remdesivir for the treatment of Covid-19. Under the ... Read More

Gilead Sciences announces Veklury EU approval for COVID-19 treatment

pharmanewsdaily- July 6, 2020 0

Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from the European Commission as a treatment for SARS-CoV-2 ... Read More

Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics

pharmanewsdaily- June 25, 2020 0

Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also ... Read More

Gilead Covid-19 drug candidate remdesivir delivers desired results in phase 3 trial

pharmanewsdaily- June 2, 2020 0

Remdesivir clinical trial results : Gilead Sciences said that the phase 3 SIMPLE trial, which has been evaluating the Covid-19 drug candidate remdesivir for the ... Read More

FDA grants EUA for Gilead’s investigational COVID-19 drug remdesivir

pharmanewsdaily- May 4, 2020 0

Remdesivir EUA status : The US has officially pushed the use of remdesivir for treating the novel coronavirus with the Food and Drug Administration (FDA) ... Read More